×
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.35 (+1.74%)
MSFT   262.22 (+1.02%)
META   167.62 (+4.74%)
GOOGL   2,266.73 (+4.23%)
AMZN   113.77 (+3.84%)
TSLA   697.13 (+2.25%)
NVDA   149.13 (+2.69%)
NIO   22.13 (+3.60%)
BABA   119.65 (+3.15%)
AMD   74.80 (+1.53%)
MU   56.75 (+5.78%)
CGC   2.71 (-3.56%)
T   21.13 (-0.84%)
GE   61.95 (-2.50%)
F   11.17 (-1.33%)
DIS   97.01 (+0.90%)
AMC   12.73 (-5.91%)
PFE   51.58 (-1.40%)
PYPL   74.32 (+4.09%)
NFLX   185.19 (+2.91%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.35 (+1.74%)
MSFT   262.22 (+1.02%)
META   167.62 (+4.74%)
GOOGL   2,266.73 (+4.23%)
AMZN   113.77 (+3.84%)
TSLA   697.13 (+2.25%)
NVDA   149.13 (+2.69%)
NIO   22.13 (+3.60%)
BABA   119.65 (+3.15%)
AMD   74.80 (+1.53%)
MU   56.75 (+5.78%)
CGC   2.71 (-3.56%)
T   21.13 (-0.84%)
GE   61.95 (-2.50%)
F   11.17 (-1.33%)
DIS   97.01 (+0.90%)
AMC   12.73 (-5.91%)
PFE   51.58 (-1.40%)
PYPL   74.32 (+4.09%)
NFLX   185.19 (+2.91%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.35 (+1.74%)
MSFT   262.22 (+1.02%)
META   167.62 (+4.74%)
GOOGL   2,266.73 (+4.23%)
AMZN   113.77 (+3.84%)
TSLA   697.13 (+2.25%)
NVDA   149.13 (+2.69%)
NIO   22.13 (+3.60%)
BABA   119.65 (+3.15%)
AMD   74.80 (+1.53%)
MU   56.75 (+5.78%)
CGC   2.71 (-3.56%)
T   21.13 (-0.84%)
GE   61.95 (-2.50%)
F   11.17 (-1.33%)
DIS   97.01 (+0.90%)
AMC   12.73 (-5.91%)
PFE   51.58 (-1.40%)
PYPL   74.32 (+4.09%)
NFLX   185.19 (+2.91%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.35 (+1.74%)
MSFT   262.22 (+1.02%)
META   167.62 (+4.74%)
GOOGL   2,266.73 (+4.23%)
AMZN   113.77 (+3.84%)
TSLA   697.13 (+2.25%)
NVDA   149.13 (+2.69%)
NIO   22.13 (+3.60%)
BABA   119.65 (+3.15%)
AMD   74.80 (+1.53%)
MU   56.75 (+5.78%)
CGC   2.71 (-3.56%)
T   21.13 (-0.84%)
GE   61.95 (-2.50%)
F   11.17 (-1.33%)
DIS   97.01 (+0.90%)
AMC   12.73 (-5.91%)
PFE   51.58 (-1.40%)
PYPL   74.32 (+4.09%)
NFLX   185.19 (+2.91%)
NASDAQ:APVO

Aptevo Therapeutics Stock Forecast, Price & News

$3.79
+0.21 (+5.87%)
(As of 07/5/2022 02:10 PM ET)
Add
Compare
Today's Range
$3.61
$3.92
50-Day Range
$3.26
$5.68
52-Week Range
$3.03
$22.68
Volume
449 shs
Average Volume
144,020 shs
Market Capitalization
$18.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00

Aptevo Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
638.8% Upside
$28.00 Price Target
Short Interest
Healthy
3.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Aptevo Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.24) to ($5.47) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.50 out of 5 stars

Medical Sector

1000th out of 1,428 stocks

Pharmaceutical Preparations Industry

490th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aptevo Therapeutics logo

About Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Stock News Headlines

Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update
Aptevo Therapeutics: Q4 Earnings Insights
Aptevo climbs as 2021 revenue more than doubles
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
Employees
54
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$28.00
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+638.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5
Research Coverage
2 Analysts

Profitability

Net Income
$-28,460,000.00
Net Margins
-222.55%
Pretax Margin
-228.05%

Debt

Sales & Book Value

Annual Sales
$12.29 million
Book Value
$0.25 per share

Miscellaneous

Free Float
4,802,000
Market Cap
$18.99 million
Optionable
Optionable
Beta
6.14














Aptevo Therapeutics Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptevo Therapeutics stock.
View analyst ratings for Aptevo Therapeutics
or view top-rated stocks.

What is Aptevo Therapeutics' stock price forecast for 2022?

2 equities research analysts have issued 1-year price targets for Aptevo Therapeutics' shares. Their APVO stock forecasts range from $20.00 to $36.00. On average, they anticipate Aptevo Therapeutics' stock price to reach $28.00 in the next year. This suggests a possible upside of 638.8% from the stock's current price.
View analysts' price targets for Aptevo Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Aptevo Therapeutics' stock price performed in 2022?

Aptevo Therapeutics' stock was trading at $7.87 on January 1st, 2022. Since then, APVO shares have decreased by 51.8% and is now trading at $3.79.
View the best growth stocks for 2022 here
.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aptevo Therapeutics
.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings results on Thursday, May, 12th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.15) by $0.44. The biotechnology company earned $3.11 million during the quarter, compared to analyst estimates of $3.75 million. Aptevo Therapeutics had a negative trailing twelve-month return on equity of 717.67% and a negative net margin of 222.55%.
View Aptevo Therapeutics' earnings history
.

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 60, Pay $870.65k)
  • Mr. Jeffrey G. Lamothe CA, Exec. VP & CFO (Age 56, Pay $590.56k)
  • Ms. SoYoung Kwon J.D., LL.M., Sr. VP, Gen. Counsel, Corp. Affairs & HR
  • Dr. Fatih M. Uckun M.D., Ph.D., Chief Clinical Advisor & Consultant

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $3.79.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $18.99 million and generates $12.29 million in revenue each year.

How many employees does Aptevo Therapeutics have?

Aptevo Therapeutics employs 54 workers across the globe.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for Aptevo Therapeutics is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503.

This page (NASDAQ:APVO) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.